NASDAQ:ACRS
Aclaris Therapeutics Stock News
$1.17
-0.0500 (-4.10%)
At Close: Apr 24, 2024
Aclaris Announces Pricing of Public Offering of Common Stock
07:55pm, Wednesday, 09'th Jun 2021
WAYNE, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory d
Aclaris (ACRS) Announces Data on Atopic Dermatitis Candidate
12:01pm, Wednesday, 09'th Jun 2021
Aclaris (ACRS) reports encouraging preliminary top-line results from a phase IIa study evaluating its JAK 1/3 inhibitor, ATI-1777, for the treatment of moderate to severe atopic dermatitis.
Aclaris Announces Proposed Public Offering of Common Stock
04:15pm, Tuesday, 08'th Jun 2021
WAYNE, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory
RMED, HOOK, JZXN, ACRS, OPRA, CVAC Stock Prices Fall Intraday
02:41pm, Tuesday, 08'th Jun 2021
The stock prices of RMED, HOOK, JZXN, ACRS, OPRA, and CVAC have fallen noticeably today. These are the details.
Aclaris' ATI-1777 Aces Atopic Dermatitis Trial with Minimal Systemic Exposure
07:46am, Tuesday, 08'th Jun 2021
Aclaris Therapeutics Inc (NASDAQ: ACRS) has announced preliminary topline results from its Phase 2a trial evaluating ATI-1777 for moderate to severe atopic dermatitis (AD). The primary efficacy end
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
09:46am, Friday, 07'th May 2021
Aclaris (ACRS) delivered earnings and revenue surprises of -111.11% and 20.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update
07:00am, Friday, 07'th May 2021
WAYNE, Pa., May 07, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory d
Aclaris Therapeutics: A Potential Big Pharma Deal May Be In The Horizon
04:00pm, Tuesday, 02'nd Mar 2021
Aclaris Therapeutics: A Potential Big Pharma Deal May Be In The Horizon
Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA
11:18am, Wednesday, 20'th Jan 2021
Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Shares up.
Aclaris Announces Pricing of Public Offering of Common Stock
08:45am, Wednesday, 20'th Jan 2021
WAYNE, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory d
ACRS Stock Price Increases 220.24%: Why It Happened
04:46pm, Tuesday, 19'th Jan 2021
The stock price of Aclaris Therapeutics Inc (NASDAQ: ACRS) increased by 220.24% today. This is why it happened.
Aclaris Announces Proposed Public Offering of Common Stock
04:01pm, Tuesday, 19'th Jan 2021
WAYNE, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory
Why Aclaris Therapeutics Stock Skyrocketed More Than 200% Today
12:53pm, Tuesday, 19'th Jan 2021
Investors are excited about the biotech's clinical trial results.
Aclaris Therapeutics stock triples after positive data on arthritis treatment
12:13pm, Tuesday, 19'th Jan 2021
Aclaris Therapeutics stock triples after positive data on arthritis treatment
ACRS Stock Alert: Why Aclaris Therapeutics Is Up Over 200% Today
11:26am, Tuesday, 19'th Jan 2021
Aclaris Therapeutics (ACRS) stock is soaring higher on Tuesday after revealing results from a recent Phase 2a clinical trial. The post ACRS Stock Alert: Why Aclaris Therapeutics Is Up Over 200% Today
